PABLO J. CAGNONI, M.D.
President, Onyx Pharmaceuticals, Inc., a subsidiary of Amgen
Pablo J. Cagnoni, M.D., was named President of Onyx Pharmaceuticals, Inc. following Amgen's acquisition of Onyx in October 2013. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations. Prior to joining Onyx, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. He played a key role in the U.S., European and Japanese regulatory submissions and approvals of Afinitor®, Tasigna®, Signifor®, Exjade®, Jakavi® and Glivec® in various indications. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSI Pharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program.
Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology in Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
Chief Financial Officer
Bob Goeltz joined Onyx in 2013 as Chief Financial Officer. Prior to joining Onyx, Mr. Goeltz served as an Executive Director in Amgen’s Corporate Development group, focused on acquisitions and licensing. During his ten years at Amgen, he also held leadership roles in Finance supporting the Commercial and Research and Development organizations. Prior to its acquisition by Amgen, Mr. Goeltz was Director of Finance at Tularik. He began his career working in the Assurance practice for Ernst & Young. Mr. Goeltz earned an MBA from the University of California at Los Angeles and a bachelor’s degree in Business from Emory University. He is also a Certified Public Accountant (inactive).
Senior Vice President, Chief Commercial Officer
Mark McClung joined Onyx in 2014 as Senior Vice President, Chief Commercial Officer with responsibility for the U.S. Commercial team and the Onyx Global Commercial functions which collaborate with Amgen Inc. on Commercial activity outside the U.S. Prior to joining Onyx, Mr. McClung grew his career at GlaxoSmithKline (GSK) serving most recently as Vice President and Head of Global Commercial for GSK Oncology. During his tenure at GSK (and the former Glaxo & SmithKline Beecham Pharmaceuticals organizations), he held several positions of increasing responsibility within Commercial and Late-Stage Development throughout Canada, the U.S., Europe and Global, developing commercial strategies and executing launches in multiple therapeutic areas including Oncology, Inflammation and Tissue Repair, and Cardiovascular. Mr. McClung completed graduate coursework at York University in Toronto and Wharton Business School at the University of Pennsylvania, and he received a bachelor’s degree in Human Kinetics and Biomedical Sciences from the University of Guelph in Ontario, Canada.
SHABBIR ANIK, PH.D.
Senior Vice President, Technical Operations
Shabbir Anik, Ph.D. joined Onyx in 2011 as Senior Vice President, Technical Operations. Prior to joining Onyx, he led Althea Technologies as President and Chief Executive Officer. Before Althea, Dr. Anik built the global development services function at Patheon, Inc., serving as President, Global Pharmaceutical Development Services and Chief Scientific Officer. Dr. Anik earned a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, an MBA from Santa Clara University and a bachelor’s degree in Pharmacy from the University of Bombay’s Institute of Chemical Technology.
BARBARA KLENCKE, M.D.
Senior Vice President, Development
Barbara Klencke, M.D. is Senior Vice President, Development responsible for the development functions of Biometrics, Clinical Operations, Clinical Science, Medical Writing, Regulatory Affairs and Project Management. She joined Onyx in 2011 after serving as Group Medical Director in Product Development, Oncology at Genentech, Inc. where she led clinical teams on molecules that have since made great advances for patients as marketed oncology medicines. Dr. Klencke’s interest in drug development began after a 20 year career delivering patient care, initially in nursing and then in medicine, including many years teaching medicine and pursing clinical research at the University of California at San Francisco where she also completed her training in Hematology and Oncology. She earned her medical degree at the University of California at Davis and her bachelor’s degree in Nursing from Indiana University at Bloomington.
ROSH DIAS, M.D., MRCP
Vice President, Head of Global Medical and Scientific Affairs
Rosh Dias, M.D. joined Onyx in early 2014 as Vice President, Head of Global Medical and Scientific Affairs, having had 14 years industry experience in various medical functions across several geographies. Prior to Onyx, Dr. Dias worked at Novartis for 10 years, initially serving in Global Medical Affairs, before moving to Australia as Head of Medical at Novartis Oncology, Oceania, where he led the Clinical Development and Medical Affairs teams in Australia and New Zealand. He most recently served as Vice President of Oncology Scientific Operations, U.S. Clinical Development and Medical Affairs at Novartis Oncology where he led the U.S. field medical organizations. Dr. Dias completed his medical training in London and practiced in the UK National Health Service for seven years before joining the pharmaceutical industry at Aventis in 2000, first in the UK, then moving to Global Medical Affairs. Dr. Dias earned his M.D. at Charing Cross and Westminster Medical School, London.
Vice President, Program Management and Clinical Operations
Jeff Knight is currently Vice President, Program Management and Clinical Operations. Mr. Knight joined Onyx in 2012 as Senior Director, Clinical Development, Head of Development Strategy and Operations and Head of Medical Writing. Before coming to Onyx, he held several leadership roles of increasing responsibility in Clinical Operations, Clinical Regulatory Affairs, and Project Management at Genentech, Inc. Prior to his tenure at Genentech, Mr. Knight held positions in Clinical Operations and Program Management at PRA International, Hoechst Marion Roussel, Inc (now Sanofi), and the University of Oklahoma Health Sciences Center. Mr. Knight also worked as a critical care nurse at the University of Kansas Hospital. Mr. Knight holds a master’s of public health degree in Biostatistics and Epidemiology from the University of Oklahoma Health Sciences Center. He also earned a bachelor’s degree in Nursing with honors from the University of Kansas Medical Center, and a bachelor’s degree in Psychology from the University of Oklahoma.
STEFANI A. WOLFF
Vice President, Global Product Team Leader
Stefani A. Wolff is Vice President, Global Product Team Leader for oprozomib and Nexavar® product teams. Ms. Wolff joined Onyx in 2013 to lead oprozomib development and commercialization to global approval. She previously held leadership positions across Genentech Inc.’s Development and Commercial organizations including Project Team Leader for the company’s B-cell portfolio of seven products, including Rituxan. Her commercial work included launching Rituxan and running Advisory and Thought Leader Services for all the products in their portfolio. Ms. Wolff also provided launch planning consulting services to Onyx and Pharmacyclics prior to joining Onyx in her current role. She earned a bachelor’s degree with highest honors in Pharmacy and also one in Chemistry from the University of North Carolina, Chapel Hill.
GARLAN ADAMS, J.D.
Associate General Counsel and Head of Law
Garlan Adams joined Onyx in 2013 as Associate General Counsel and Head of Law. Prior to Onyx, she joined Amgen Inc. in 2009 as Director, Global Commercial Law Department, supporting the Nephrology and Oncology Business Units as well as Compliance and the Commercial Center of Excellence. Before her tenure at Amgen, Ms. Adams was a director in the Legal department at Amylin Pharmaceuticals, Inc. after serving as Customer Business Solutions Manager at Eli Lilly and Company. In that role at Lilly, she developed pricing strategies, draft terms and conditions for contracting for all U.S. products in hospitals, group purchasing organizations and long-term care institutions. She was also the lead attorney for Lilly’s Insulin products for 3 years within the U.S. Law Division. Ms. Adams graduated cum laude at the Indiana University School of Law and earned a bachelor’s degree in History from St. Francis College.
Head of Human Resources
Head of Corporate Affairs
Lori Melançon serves as Head of Corporate Affairs, overseeing a team that manages corporate communications, global product public relations, patient advocacy relations and internal communications, and provides investor relations support to Amgen for Onyx products. She joined Onyx in 2009. Prior to Onyx, Ms. Melançon led healthcare communications programs at WeissComm Partners, now W2O Group, a public relations firm, where she provided strategic counsel to executive management teams on corporate and product public relations programs for biopharmaceutical and molecular diagnostic companies. Prior to WeissComm, she served in roles of increasing responsibility at Applied Biosystems and ReGen Biologics, Inc., now Ivy Sports Medicine. Ms. Melançon earned an MBA from the University of San Francisco and a bachelor’s degree in Rhetoric and Communications from the University of California at Davis.
GLENNA SHEN, J.D.
Head of Compliance
Glenna Shen serves as Head of Compliance at Onyx. Ms. Shen came to Onyx from Amgen Inc., which she joined in 2000, and worked in the Employment Law and Global Commercial Operations Law Groups before leaving the company in 2005 to pursue an opportunity as Vice President, Law for Hilton Hotels Corporation. She rejoined the Amgen Global Commercial Operations Law Group in 2009 where she provided legal support for all commercial aspects of Amgen’s biosimilars strategy, including policy, advocacy and education. She started her current role in 2013. Ms. Shen earned her J.D. and master’s degree in Business Taxation from the University of Southern California and a bachelor’s degree in Biology from the University of Miami.
CHRISTINE M. O'BRIEN
Senior Director, Strategic Operations
Christine O’Brien joined Onyx in 2014 as Senior Director, Strategic Operations and serves as Chief of Staff to Pablo Cagnoni, Onyx President. Ms. O’Brien came to Onyx from Amgen, Inc. where she held positions of increasing responsibility in project management and training and development. Prior to joining Amgen, Christine worked as a consultant for Accenture in the Change Management Practice for the pharmaceutical industry. She earned a master’s degree in Management and Leadership from Pepperdine University and bachelor’s degrees in Labor Studies and Psychology from Pennsylvania State University.